Phase I Study of TAK-701 in Adult Patients With Advanced Nonhematological Malignancies

NCT ID: NCT00831896

Last Updated: 2011-12-02

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 27 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-03-31
• Study Completion Date: 2011-05-31

Brief Summary

This study is a multicenter, open-label, dose escalation, phase 1 study of TAK 701 in adult patients with advanced nonhematologic malignancies. This study will be the first to administer TAK 701 to humans. The primary purpose of this study is to determine the safety profile, tolerability, and pharmacokinetics profile of TAK-701.

Conditions

Advanced Solid Tumors

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

1

TAK-701

Group Type: EXPERIMENTAL

TAK-701

Intervention Type: BIOLOGICAL

Either 2, 5, 10, or 20 mg/kg IV. Cycle 1: single dose at 2x the dose assignment; Cycle 2 and beyond: dose once every two weeks

Dosing continues until disease progression, unacceptable toxicity related to TAK-701, or maximum of 12 cycles, unless determined that patient would benefit from continued therapy.

Interventions

TAK-701

Either 2, 5, 10, or 20 mg/kg IV. Cycle 1: single dose at 2x the dose assignment; Cycle 2 and beyond: dose once every two weeks

Dosing continues until disease progression, unacceptable toxicity related to TAK-701, or maximum of 12 cycles, unless determined that patient would benefit from continued therapy.

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. Male or female patients aged 18 years or older.

2. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.

3. Diagnosis of a nonhematologic malignancy for which standard curative or lifeprolonging treatment does not exist or is no longer effective.

4. Radiographically or clinically evaluable tumor; however, measurable disease is not required for participation in this study (eg, patients with pleural effusion or ascites).

5. Female patients who:

• Are postmenopausal for at least 1 year before the screening visit, or
• Are surgically sterile, or
• If they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 3 months after the last dose of study drug, or agree to completely abstain from heterosexual intercourse.

Male patients, even if surgically sterilized (ie, status postvasectomy), who:

• Agree to practice effective barrier contraception during the entire study drug treatment period and through 3 months after the last dose of TAK-701, or
• Agree to completely abstain from heterosexual intercourse.

6. Voluntary written consent must be given before performance of any study-related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care.

Exclusion Criteria

1. Female patients who are lactating or have a positive serum pregnancy test during the screening period.

2. Major surgery within 14 days before the first dose of TAK-701 or any planned/anticipated surgery during the study period.

3. Positive test for Hepatitis B or C infection.

4. Active alcohol abuse

5. Active infection requiring systemic therapy, or other serious infection.

6. Antineoplastic therapy (including unconjugated therapeutic antibodies and toxin immunoconjugates) or any experimental therapy within 21 days before the first dose of TAK-701.

7. Radiotherapy within 21 days before the first dose of TAK-701.

8. Nitrosoureas or mitomycin-C within 6 weeks before the first dose of TAK-701.

9. Autologous stem cell transplant within 3 months before the first dose of TAK-701, or prior allogeneic stem cell transplant at any time.

10. Any prior exposure to anti-HGF therapy (eg, AMG-102, AV-299).

11. The patient has symptomatic brain metastasis.

12. Absolute neutrophil count < 1,500/mm3; platelet count < 100,000/mm3.

13. Calculated creatinine clearance < 50mL/minute

14. Any of the following clinical laboratory results during screening (ie, within 28 days before the first dose of TAK-701):

• Bilirubin > 1.5 times the upper limit of the normal range (ULN).
• Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 times the ULN. AST and ALT may be elevated up to 5 times the ULN if their elevation can be reasonably ascribed to the presence of metastatic disease to liver and/or to bone.

15. Known human immunodeficiency virus (HIV) positive.

16. Serious medical or psychiatric illness likely to interfere with participation in this clinical study.

17. Uncontrolled cardiovascular condition, including ongoing cardiac arrhythmias, congestive heart failure, angina, or myocardial infarction within the past 6 months.

18. Patients having QTc > 470 msec on a 12-lead ECG obtained within 28 days before first study drug administration.

19. Presence of serious or nonhealing wound, ulcer or bone fracture.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Millennium Pharmaceuticals, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Medical Monitor

Role: STUDY_DIRECTOR

Millennium Pharmaceuticals, Inc.

Locations

Emory University School of Medicine, Winship Cancer Institute

Atlanta, Georgia, United States

Fox Chase Cancer Center

Philadelphia, Pennsylvania, United States

The Sarah Cannon Research Institute

Nashville, Tennessee, United States

Countries

United States

Other Identifiers

C17001

Identifier Type: -

Identifier Source: org_study_id